Alkaline Phosphatase (ALP) is an enzyme present in bone and liver that rises when bone is actively remodeling or when the bile ducts are blocked or inflamed. In healthy adults, ALP typically reflects a mixture of liver and bone activity; elevated ALP combined with elevated GGT strongly suggests cholestasis (biliary obstruction), while elevated ALP with normal GGT suggests bone turnover. ALP is a longevity marker because persistently elevated levels can signal either metabolic dysfunction (hepatic) or accelerated bone loss (skeletal), both of which predict long-term health decline.
Analyzed in accredited Swedish clinical laboratories (ISO 15189). Used to support clinician-directed evaluation and monitoring. Not a stand-alone diagnosis.
If you have a family history of liver disease, metabolic syndrome, or early osteoporosis, or if you're monitoring your bone health as you age, an ALP test provides clarity on two of the body's most critical long-term systems. ALP is one of the first markers to flag silent hepatic inflammation (especially when paired with GGT) or accelerated bone turnover, both of which require different clinical responses.
ALP is part of standard Swedish blood panels (along with ALT, AST, and GGT), making it one of the most accessible markers for surveillance. If you've never had one measured, it's a simple way to establish your baseline hepatic and bone activity — particularly important if you have risk factors for liver dysfunction or if you're in your 60s and want to track skeletal integrity.
Flags cholestasis and biliary obstruction. When ALP is elevated alongside GGT, it reliably points to obstruction or inflammation of the bile ducts — a finding that demands further investigation and can signal serious hepatic compromise if left untreated.
Distinguishes bone turnover from liver dysfunction. Elevated ALP paired with normal GGT suggests active bone remodeling (healing fracture, Paget's disease, or metabolic bone disease) rather than liver disease, narrowing your diagnostic focus immediately.
Tracks metabolic and endocrine health. ALP rises in hyperthyroidism, hyperparathyroidism, and vitamin D deficiency — conditions that accelerate bone loss and systemic metabolic aging. This makes it a useful proxy marker for broader metabolic status.
Detects occult hepatic inflammation. ALP can be elevated even when transaminases (ALT, AST) are normal, catching silent inflammatory hepatic disease that standard liver enzymes might miss.
Predicts fracture risk over time. Persistently elevated ALP in older adults correlates with accelerated bone turnover and increased fracture risk, making it relevant for longevity planning and preventive orthopedic strategies.
Monitors therapeutic response. In patients on medications that affect bone or liver (e.g., bisphosphonates, antiepileptics), ALP tracks whether intervention is slowing bone remodeling or whether hepatic toxicity is emerging.
The enzyme and its sources. Alkaline Phosphatase is a ubiquitous enzyme that hydrolyzes phosphate groups from proteins and organic compounds. It exists in at least four tissue-specific isoforms — liver (hepatic biliary epithelium), bone (osteoblasts during active remodeling), intestine, and placenta. In the healthy adult, serum ALP is dominated by liver and bone contributions; the kidney does not secrete ALP, so it's not a marker of renal function.
Bone ALP and osteoblast activity. When bone is actively remodeling — during adolescent growth, fracture healing, menopause-driven osteoporosis, Paget's disease, or metastatic bone disease — osteoblasts (bone-building cells) release ALP into the bloodstream. This is why ALP rises in any state of accelerated osteoblast activity. Young adolescents naturally have higher ALP (up to 300–400 U/L) because their skeleton is growing; in older adults, persistently high ALP suggests either pathological bone turnover or metabolic conditions driving remodeling (vitamin D deficiency, hyperparathyroidism, thyroid dysfunction).
Hepatic ALP and cholestasis. The liver produces ALP in response to bile duct obstruction, inflammation, or proliferation of hepatocytes lining the biliary tree. When the normal flow of bile is blocked (by stone, stricture, pancreatic cancer compressing the duct, or cirrhosis), hepatocytes ramp up ALP production as a compensatory response. This is why ALP is one of the most sensitive markers of cholestasis — it rises faster and often higher than transaminases. When paired with GGT (gamma-glutamyl transferase, another cholestatic enzyme), the combination is nearly pathognomonic for biliary pathology.
The ALP + GGT pairing. This is the critical clinical principle: elevated ALP + elevated GGT = cholestasis (biliary/hepatic origin). Elevated ALP + normal GGT = bone origin. Because GGT is almost exclusively hepatobiliary (unlike ALP, which has bone, intestinal, and placental sources), the discordance between ALP and GGT tells you immediately where the ALP is coming from. This pairing is essential for avoiding misinterpretation.
Identifies hidden cholestasis. Silent bile duct obstruction or cirrhosis can progress without causing jaundice or abdominal pain. ALP (in conjunction with GGT and direct bilirubin) catches these early, allowing intervention before hepatic synthetic dysfunction or portal hypertension develops.
Reveals metabolic bone disease before fracture. ALP elevation in the context of low vitamin D or elevated PTH predicts accelerated bone loss and fracture risk years in advance. This is particularly important in women entering menopause and in older adults, where fracture avoidance is a major longevity lever.
Flags undiagnosed thyroid and parathyroid dysfunction. Hyperthyroidism, primary hyperparathyroidism, and secondary hyperparathyroidism (from vitamin D deficiency) all elevate ALP. These conditions are common, often asymptomatic, and directly damage skeletal and cardiovascular health; ALP is an early warning signal.
Guides interpretation of other markers. ALP contextualizes transaminases (ALT, AST) and bilirubin. If ALT is mildly elevated but ALP and GGT are high, you're dealing with cholestasis, not hepatocellular injury — a difference with major treatment implications.
Standard Swedish reference range (vårdcentralen): 35–105 U/L for adults at rest. This range varies slightly by laboratory and is higher in adolescents (up to 300 U/L during peak growth) and children; verify your lab's age- and sex-specific cutoffs.
Loovi optimal (longevity focus): 35–75 U/L. This tighter upper bound reduces the likelihood of undetected metabolic bone disease or chronic low-grade cholestasis in adults.
Elevated (investigative threshold): > 105 U/L warrants pairing with GGT and direct bilirubin to distinguish cholestasis from bone turnover.
The key insight: normal does not equal optimal. Many adults with ALP in the 90–110 U/L range have silent metabolic bone disease (especially if vitamin D is low) or mild, undiagnosed cholestasis. In longevity medicine, keeping ALP < 75 U/L is a useful target for ruling out these slow-moving pathologies.
Low ALP (< 25 U/L). Uncommonly low ALP is unusual in healthy adults and warrants investigation. It can signal hypophosphatasia (a genetic disorder affecting bone mineralization), severe zinc or magnesium deficiency, hypothyroidism, or Wilson disease. Low ALP can also transiently occur after cardiac surgery or severe protein malnutrition. If your ALP is persistently low, further testing should include zinc, magnesium, thyroid function, and (if clinically indicated) ceruloplasmin for Wilson disease screening.
Normal-to-optimal ALP (35–75 U/L). This range reflects stable bone turnover and normal hepatic and biliary function. In the context of normal GGT, bilirubin, and liver enzymes, you can be confident that neither bone disease nor cholestasis is present. ALP in this range is associated with lower fracture risk and absence of biliary pathology.
Mildly elevated ALP (75–130 U/L). This is the zone where clinical judgment matters most. Paired with normal GGT, it often reflects brisk bone turnover (healing fracture, adolescent growth, early menopause-driven loss, or vitamin D deficiency with secondary hyperparathyroidism). Paired with elevated GGT and elevated or borderline elevated direct bilirubin, it suggests cholestasis that may require imaging (ultrasound or MRCP) to rule out obstruction. In pregnancy (especially 3rd trimester), ALP can rise to 160–180 U/L physiologically due to placental ALP — this is benign and resolves postpartum.
Markedly elevated ALP (> 200 U/L). This degree of elevation almost always indicates either severe cholestasis (biliary obstruction, cirrhosis, drug-induced liver injury) or significant bone pathology (Paget's disease, extensive bone metastases, severe hyperparathyroidism, or massive fracture healing). Marked ALP elevation is never normal in the adult and mandates urgent investigation, including GGT, bilirubin, imaging, and often specialist referral.
Factors that influence ALP. Pregnancy (3rd trimester), acute illness, recent fracture, adolescence (normal and expected), medications (anticonvulsants, steroids, and some lipid-lowering drugs can raise ALP), vitamin D deficiency, hyperparathyroidism, hyperthyroidism, alcohol-induced liver disease, and hemolysis (pseudolow values if serum is icteric) all affect ALP. Fasting is not required for ALP measurement, and time-of-day variation is minimal.
Bone-driven elevation. Adolescent growth, fracture healing, Paget's disease, bone metastases (especially from breast, lung, prostate), primary or secondary hyperparathyroidism, hyperthyroidism, vitamin D deficiency with secondary hyperparathyroidism, and osteomalacia all increase ALP by driving osteoblast activity. In older adults, the combination of low vitamin D and rising ALP is a red flag for metabolic bone disease and fracture risk.
Hepatobiliary obstruction and inflammation. Gallstones blocking the bile duct, biliary strictures, pancreatic cancer compressing the duct, cirrhosis, primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), alcohol-induced liver disease, and viral or autoimmune hepatitis all elevate ALP. The ALP + GGT pairing is your diagnostic compass: if both are high, the source is hepatobiliary; if ALP is high alone, it's not.
Medications and toxins. Anticonvulsants (phenytoin, phenobarbital), corticosteroids (especially at high doses and chronically), some statins, and anabolic steroids can elevate ALP. Acute drug-induced liver injury (e.g., from acetaminophen overdose or hepatotoxic drugs) usually raises transaminases more than ALP, but cholestatic drug reactions preferentially raise ALP and GGT.
Endocrine and metabolic drivers. Hyperthyroidism, primary hyperparathyroidism, and secondary hyperparathyroidism from vitamin D deficiency all independently drive bone turnover and raise ALP. Conversely, hypothyroidism and hypoparathyroidism lower ALP by suppressing bone remodeling.
Physiological and age-related factors. Adolescents and young adults in growth phases naturally have higher ALP. Pregnancy (especially 3rd trimester) can raise ALP to > 160 U/L due to placental contribution — this is benign. Postmenopausal women have accelerated bone turnover and higher baseline ALP; this normalizes somewhat on hormone therapy but persists as a marker of skeletal aging.
Vitamin D and calcium sufficiency. The single most powerful lever for controlling ALP is maintaining vitamin D > 50 nmol/L (and optimally > 75 nmol/L) and adequate calcium intake. Vitamin D deficiency triggers secondary hyperparathyroidism, which drives osteoblasts to accelerate bone turnover and release ALP. Correcting vitamin D deficiency is often sufficient to normalize ALP in the context of metabolic bone disease.
Thyroid optimization. Both hyperthyroidism and hypothyroidism affect ALP; ensuring euthyroid status (TSH in the upper-normal range and free T4 in the middle tertile) reduces unnecessary bone remodeling signaling. Subclinical hyperthyroidism is particularly problematic for bone and should be corrected.
Addressing primary hyperparathyroidism. If elevated ALP is driven by elevated PTH (from primary hyperparathyroidism), surgical parathyroidectomy is the definitive intervention. Medical management (cinacalcet) is available if surgery is declined, but the PTH-lowering effect is often modest.
Weight-bearing exercise and mechanical loading. Bone responds to load. Weight-bearing and resistance training maintain or build bone mineral density, which stabilizes ALP at lower levels by reducing the stimulus for accelerated remodeling. The effect is most pronounced in postmenopausal women and older adults.
Inflammation and hepatic health. If elevated ALP is cholestasis-driven (high GGT, elevated bilirubin), the focus shifts to identifying and resolving obstruction or inflammation. Alcohol cessation, management of underlying autoimmune hepatitis or PBC, treatment of viral hepatitis, and discontinuation of hepatotoxic medications are the levers — not supplements. Metformin has been shown to improve fibrosis markers in some metabolic liver disease, but it does not directly lower ALP.
Optimizing ALP is not about suppressing it artificially — it's about normalizing the underlying drivers. The right approach depends on whether ALP is bone-driven or hepatic-driven, which is where the GGT and bilirubin context becomes essential. A Loovi longevity doctor maps out your full biomarker profile to determine which lever applies to you.
ALP is a sentinel, not a diagnosis. Elevated ALP could point to five completely different pathologies (bone disease, cholestasis, drug toxicity, thyroid dysfunction, or parathyroid disease), and a single number tells you none of them definitively. This is why ALP must always be interpreted alongside GGT (to distinguish bone from liver), total and direct bilirubin (to assess cholestatic severity), ALT and AST (to assess hepatocellular injury), vitamin D and PTH (to assess mineral metabolism), TSH and free T4 (to rule out thyroid disease), and calcium (to complete the metabolic bone picture).
In longevity medicine, you need the full constellation: ALP, GGT, ALT, AST, bilirubin, albumin, vitamin D, PTH, calcium, magnesium, TSH, and free T4. This is exactly why Loovi's membership model tracks 120+ biomarkers annually. One marker in isolation is noise; the full picture, interpreted by a longevity doctor in conversation with you, is signal. Your ALP is telling you something real — but to act on it wisely, you need to hear the full story.
This is a classic cholestatic pattern. If GGT is also elevated, you almost certainly have bile duct obstruction or inflammation (from gallstones, pancreatic disease, or primary biliary cholangitis) rather than hepatocellular injury. If GGT is normal and ALP is elevated alone, bone turnover is driving the ALP — common in vitamin D deficiency, hyperparathyroidism, or healing fracture. Transaminases (ALT, AST) reflect hepatocyte death and are normal in cholestasis because the liver cells themselves are intact; they're being squished by backed-up bile, not dying.
Not directly, and supplements marketed for “liver support” have limited evidence. The exception: vitamin D deficiency causing secondary hyperparathyroidism is directly correctable with vitamin D repletion, which will lower both PTH and ALP. Magnesium and zinc support bone health broadly, but they won't move ALP if it's driven by cholestasis or Paget's disease. Address the root cause — bone disease, thyroid disease, or biliary obstruction — and ALP follows.
Anticonvulsants, steroids, and some lipid-lowering drugs are known to raise ALP, either by inducing hepatic enzyme expression or by stimulating bone turnover. This is usually benign and resolves when the drug is stopped, but if ALP rises sharply or you develop GGT elevation alongside it, notify your doctor. Do not stop the medication on your own, but do flag the trend.
Yes, in the 3rd trimester. ALP can rise to 160–180 U/L — sometimes even higher — due to placental ALP contribution. This is physiological and benign; it resolves within weeks postpartum. If ALP is elevated in early pregnancy or persists well after delivery, it warrants investigation for cholestasis of pregnancy or underlying liver disease, which are rare but serious.
No. ALP is not affected by fed vs. fasted state. You can eat and drink normally before the test. Time of day does not significantly affect ALP, though like most labs it's best drawn in the morning when possible for consistency.
Not inherently, but markedly elevated ALP (especially > 300 U/L) can reflect bone metastases from cancer, and very high ALP can be seen in advanced cirrhosis or hepatocellular carcinoma. In isolation, elevated ALP is far more likely to reflect benign causes (bone healing, vitamin D deficiency, cholestasis from gallstones). However, if ALP is very high and you have constitutional symptoms (weight loss, fatigue, abdominal pain), imaging and specialist referral are warranted.
This depends on the cause. If elevated ALP is driven by vitamin D deficiency, repletion typically lowers ALP over 8–12 weeks as PTH normalizes and osteoblasts calm down. If cholestasis is from a blocked bile duct, relief of obstruction (via endoscopic removal of stone or stent placement) can lower ALP within days to weeks. If ALP is from bone metastases or Paget's disease, response to treatment is slower — weeks to months. Always discuss expected timelines with your clinician.
Rarely. Very low ALP is unusual and can indicate hypophosphatasia (a genetic mineralization disorder), severe malnutrition, severe hepatic disease with cirrhosis and synthetic dysfunction (the liver can no longer make ALP), or Wilson disease. If ALP is persistently < 20 U/L, further investigation for rare genetic or metabolic disease is warranted, but this is uncommon.
Yes. There is genetic variation in baseline ALP, and bone density and turnover vary between individuals. Some people naturally have ALP in the 40–50 U/L range; others stay in the 80–100 U/L range without pathology. This is why establishing your own baseline and tracking it over time is more informative than comparing yourself to population ranges. A Loovi longevity doctor helps you interpret your ALP in the context of your genetics, age, sex, and full biomarker picture.
